City of Hope

Integrated Dna Technologies, Inc.

California Institute of Technology

Apterna Limited

University of California

The Scripps Research Institute

The General Hospital Corporation

Calando Pharmaceuticals, Inc.

City of Hope Research Institute

Apierna Ltd

City of Hopw

Clty of Hope

John J Rossi

Dongho Kim

Mark Aaron Behlke

Jiehua Zhou

Sorah Yoon

William A Goddard, Iii

Piotr Marek Swiderski

Nagy Habib

Lisa Scherer

Nan-Sook Lee

Richard Jove

Hua Yu

Marcin Tomasz Kortylewski

Edouard M Cantin

Si-ping Han

Britta Vallazza

John A Zaia

Daniela Castanotto

Pal Saetrom

Lars Aagaard

Jane Zhang

Ali Ehsani

Ola Snove

Jeffrey I Zink

Fuyuhiko Tamanoi

Kevin V Morris

Carlotta A Glackin

Si-Ping Han

Pairoj Chang

James Finlay

Cai M Roberts

Katrin Tiemann

Patric Lundberg

Maggie Bobbin

Arthur D Riggs

R Bruce Wallace

John C Burnett

Marc Weinberg

Nerida Taylor

Marwa Ben Haj Salah

Alessandro Michienzi

Michaela Scherr

Elizabeth Epps

Britta Hoehn

Mayumi Takahashi

Mark E Davis

Steve S Sommer

Guido Marcucci

Keiichi Itakura

Ya-Huei Kuo

Bruce E Kaplan

Jeremy D Heidel

Gerd P Pfeifer

Garry P Larson

Hoshang Unwalla

Laurence Cagnon

George J Murakawa

Daniel H Kim

Stella Tommasi

Ulrike Jung

Saumya Das

Ane Miren Salvador Garicano

Julia Derogatis

Sahil Sagar

Ka Ming Pang

Robin Hu

Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.

Conditional-siRNAS and uses thereof in treating cardiac hypertrophy

Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells. The aptamers can be used as a therapeutic agent by itself or in combination with a small molecule by forming a conjugate with the small molecule. Targeted delivery of the small molecule can be achieved by such conjugates. Also disclosed are methods of treating a subject suffering from cancer by administering an effective amount of the aptamer or the aptamer-small molecule conjugate to the subject.

CCR7 aptamers and uses thereof

Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.

Bi specific aptamer

Disclosed herein are multi-way oligonucleotide junctions for delivering one or more cargo molecules to a biological target and method of making such junctions. The oligonucleotide junctions are formed by two or more oligonucleotides and are stable outside the cell and easily dissociate inside the cell to release the cargo molecule(s). One or more cargo molecules as well as delivery ligand can be loaded to the junctions for targeted delivery. Also disclosed are nanostructures including one or more junctions attached to each other for delivering two or more cargo molecules.

Meta-stable oligonucleotides junctions for delivery of therapeutics

Disclosed herein are programmable, conditionally activated small interfering RNA constructs (Cond-siRNAs) and methods of making and using the same as therapeutic agents. The Cond-siRNA comprises a sensor strand, a core strand, and a guide strand, which crossover to form a sensor duplex and a RNAi duplex attached to each other to form a single structure. Upon binding an input strand to the sensor strand, the Cond-siRNA is activated and releases RNAi targeting a desired gene.

Programmable conditional SIRNAS and uses thereof

The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.

Twist signaling inhibitor compositions and methods of using the same

Provided are aptamer compositions and their use for treating cancer.

Aptamer compositions and the use thereof

Provided herein are, inter alia, oligonucleotides, kits, and methods useful for increasing lentiviral titers.

Splice inhibiting oligonucleotides

Disclosed herein are conditional siRNAs activatable by CBF&#x3b2;-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Conditional-siRNAS and uses thereof in treating acute myeloid leukemia

A ribonucleic acid compound is disclosed, the ribonucleic acid compound comprising, or consisting of, an RNA sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein said RNA sequence has a length of 29 nucleotides or fewer, and wherein the RNA sequence is capable of binding to a transferrin receptor (TfR).

RNA aptamers against transferrin receptor (TfR)

Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.

Anti-cancer RNA aptamers

Provided herein, inter alia, are nucleic acid compounds capable of binding transferrin receptor on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.

RNA aptamers against transferrin receptor (TFR)

Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors.

P38 map kinase inhibitors

Bi-specific aptamer

Growing community of inventors

Alta Loma, CA, United States of America

John J Rossi